The First Clinical College of China Medical University, Shenyang, Liaoning, China.
Laboratory Animal Science of China Medical University, Shenyang, Liaoning, China.
Front Immunol. 2024 Nov 13;15:1492546. doi: 10.3389/fimmu.2024.1492546. eCollection 2024.
Drug resistance poses a significant challenge in the treatment of breast cancer. In recent years, a variety of nanomaterials have been discovered and synthesized that can selectively target tumor cells and play a crucial role in the advancement of breast cancer therapies. As our understanding of tumor heterogeneity deepens, the emerging potential of nanomaterials in addressing drug resistance has garnered considerable attention. These materials not only selectively target tumor cells but also possess unique properties that make them promising options for cancer treatment, including low toxicity, excellent biocompatibility, ease of preparation, the ability to carry antitumor drugs, and customizable surface functions. In this review, we will comprehensively summarize two key developments in breast cancer treatment: the application of antitumor drugs and nanomaterials. We will explore the mechanisms by which nanomaterials improve drug resistance in breast cancer, targeted nanotherapy strategies to mitigate this resistance, and recent research advancements in anticancer nanomaterials. This overview aims to highlight the significant role of nanomaterials in breast cancer treatment and provide a theoretical framework for identifying optimal treatment strategies in the future.
耐药性是乳腺癌治疗的重大挑战。近年来，发现并合成了多种纳米材料，这些材料能够选择性地针对肿瘤细胞，并在乳腺癌治疗的进展中发挥关键作用。随着我们对肿瘤异质性的理解不断加深，纳米材料在解决耐药性方面的新兴潜力引起了广泛关注。这些材料不仅选择性地针对肿瘤细胞，而且具有独特的性质，使其成为癌症治疗的有前途的选择，包括低毒性、良好的生物相容性、易于制备、携带抗肿瘤药物的能力以及可定制的表面功能。在这篇综述中，我们将全面总结乳腺癌治疗中的两个关键进展：抗肿瘤药物和纳米材料的应用。我们将探讨纳米材料改善乳腺癌耐药性的机制、减轻这种耐药性的靶向纳米治疗策略以及抗癌纳米材料的最新研究进展。这篇综述旨在强调纳米材料在乳腺癌治疗中的重要作用，并为未来确定最佳治疗策略提供理论框架。
